Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 29578 | 17.68 |
09:34 ET | 12418 | 17.6624 |
09:36 ET | 5100 | 17.6584 |
09:38 ET | 2727 | 17.65 |
09:39 ET | 3691 | 17.6 |
09:41 ET | 4392 | 17.6 |
09:43 ET | 3800 | 17.6004 |
09:45 ET | 7160 | 17.6 |
09:48 ET | 4107 | 17.59 |
09:50 ET | 7227 | 17.575 |
09:52 ET | 9628 | 17.56 |
09:54 ET | 8714 | 17.62 |
09:56 ET | 10652 | 17.5757 |
09:57 ET | 4325 | 17.545 |
09:59 ET | 2541 | 17.54 |
10:01 ET | 14823 | 17.545 |
10:03 ET | 58098 | 17.66 |
10:06 ET | 14471 | 17.6 |
10:08 ET | 9502 | 17.56 |
10:10 ET | 7501 | 17.58 |
10:12 ET | 7970 | 17.57 |
10:14 ET | 5300 | 17.59 |
10:15 ET | 9859 | 17.63 |
10:17 ET | 750 | 17.625 |
10:19 ET | 3127 | 17.63 |
10:21 ET | 2108 | 17.605 |
10:24 ET | 5142 | 17.59 |
10:26 ET | 4410 | 17.585 |
10:28 ET | 4624 | 17.56 |
10:30 ET | 6440 | 17.525 |
10:32 ET | 15181 | 17.5105 |
10:33 ET | 2601 | 17.54 |
10:35 ET | 1700 | 17.54 |
10:37 ET | 11274 | 17.62 |
10:39 ET | 8853 | 17.5993 |
10:42 ET | 4400 | 17.61 |
10:44 ET | 1502 | 17.59 |
10:46 ET | 1550 | 17.6 |
10:48 ET | 8316 | 17.58 |
10:50 ET | 2202 | 17.555 |
10:51 ET | 7779 | 17.56 |
10:53 ET | 2100 | 17.545 |
10:55 ET | 9493 | 17.55 |
10:57 ET | 1921 | 17.545 |
11:00 ET | 4362 | 17.55 |
11:02 ET | 6493 | 17.56 |
11:04 ET | 5522 | 17.52 |
11:06 ET | 1400 | 17.545 |
11:08 ET | 1121 | 17.53 |
11:09 ET | 1106 | 17.54 |
11:11 ET | 2221 | 17.51 |
11:13 ET | 14171 | 17.485 |
11:15 ET | 13050 | 17.46 |
11:18 ET | 14610 | 17.41 |
11:20 ET | 6278 | 17.4331 |
11:22 ET | 4367 | 17.435 |
11:24 ET | 2251 | 17.46 |
11:26 ET | 700 | 17.465 |
11:27 ET | 4400 | 17.48 |
11:29 ET | 13540 | 17.4625 |
11:31 ET | 9020 | 17.495 |
11:33 ET | 3806 | 17.475 |
11:36 ET | 3483 | 17.5 |
11:38 ET | 7188 | 17.545 |
11:40 ET | 17045 | 17.53 |
11:42 ET | 805 | 17.54 |
11:44 ET | 2902 | 17.59 |
11:45 ET | 3565 | 17.5624 |
11:47 ET | 5189 | 17.53 |
11:49 ET | 2625 | 17.535 |
11:51 ET | 2900 | 17.535 |
11:54 ET | 1701 | 17.525 |
11:56 ET | 1470 | 17.52 |
11:58 ET | 1558 | 17.505 |
12:00 ET | 9349 | 17.515 |
12:02 ET | 4220 | 17.48 |
12:03 ET | 2094 | 17.51 |
12:05 ET | 1456 | 17.5 |
12:07 ET | 7261 | 17.5018 |
12:09 ET | 2850 | 17.51 |
12:12 ET | 2876 | 17.5 |
12:14 ET | 3496 | 17.475 |
12:16 ET | 5080 | 17.47 |
12:18 ET | 13329 | 17.495 |
12:20 ET | 2084 | 17.485 |
12:21 ET | 1800 | 17.495 |
12:23 ET | 1872 | 17.485 |
12:25 ET | 4720 | 17.485 |
12:27 ET | 400 | 17.495 |
12:30 ET | 800 | 17.495 |
12:32 ET | 8876 | 17.52 |
12:34 ET | 3600 | 17.5 |
12:36 ET | 100 | 17.491 |
12:38 ET | 400 | 17.491 |
12:39 ET | 600 | 17.495 |
12:41 ET | 9525 | 17.495 |
12:43 ET | 300 | 17.495 |
12:45 ET | 200 | 17.495 |
12:48 ET | 3352 | 17.52 |
12:50 ET | 800 | 17.52 |
12:52 ET | 8288 | 17.5 |
12:54 ET | 3603 | 17.5 |
12:56 ET | 5611 | 17.47 |
12:57 ET | 196368 | 17.4 |
12:59 ET | 9010 | 17.3981 |
01:01 ET | 5535 | 17.4 |
01:03 ET | 6649 | 17.43 |
01:06 ET | 3557 | 17.44 |
01:08 ET | 2198 | 17.445 |
01:10 ET | 7413 | 17.485 |
01:12 ET | 7290 | 17.46 |
01:14 ET | 2764 | 17.48 |
01:15 ET | 2798 | 17.495 |
01:17 ET | 3269 | 17.505 |
01:19 ET | 625 | 17.515 |
01:21 ET | 9068 | 17.525 |
01:24 ET | 1844 | 17.505 |
01:26 ET | 1892 | 17.485 |
01:28 ET | 981 | 17.495 |
01:30 ET | 2808 | 17.48 |
01:32 ET | 300 | 17.495 |
01:33 ET | 12216 | 17.4798 |
01:35 ET | 8350 | 17.465 |
01:37 ET | 17562 | 17.51 |
01:39 ET | 2600 | 17.51 |
01:42 ET | 200 | 17.51 |
01:44 ET | 5043 | 17.52 |
01:46 ET | 1501 | 17.52 |
01:48 ET | 3713 | 17.505 |
01:50 ET | 3900 | 17.485 |
01:51 ET | 5690 | 17.5 |
01:53 ET | 1000 | 17.51 |
01:55 ET | 3767 | 17.515 |
01:57 ET | 900 | 17.51 |
02:00 ET | 3412 | 17.505 |
02:02 ET | 1578 | 17.495 |
02:04 ET | 1994 | 17.51 |
02:06 ET | 1108 | 17.52 |
02:08 ET | 3099 | 17.51 |
02:09 ET | 9772 | 17.5681 |
02:11 ET | 910 | 17.58 |
02:13 ET | 5594 | 17.545 |
02:15 ET | 850 | 17.53 |
02:18 ET | 4786 | 17.55 |
02:20 ET | 1579 | 17.545 |
02:22 ET | 625 | 17.545 |
02:24 ET | 600 | 17.545 |
02:26 ET | 5025 | 17.56 |
02:27 ET | 6006 | 17.565 |
02:29 ET | 4809 | 17.54 |
02:31 ET | 2001 | 17.54 |
02:33 ET | 1996 | 17.545 |
02:36 ET | 5079 | 17.515 |
02:38 ET | 2027 | 17.515 |
02:40 ET | 1445 | 17.525 |
02:42 ET | 1272 | 17.51 |
02:44 ET | 800 | 17.51 |
02:45 ET | 2700 | 17.535 |
02:47 ET | 500 | 17.53 |
02:49 ET | 1300 | 17.53 |
02:51 ET | 1924 | 17.53 |
02:54 ET | 895 | 17.52 |
02:56 ET | 2000 | 17.505 |
02:58 ET | 3038 | 17.49 |
03:00 ET | 6422 | 17.5 |
03:02 ET | 4972 | 17.495 |
03:03 ET | 5212 | 17.45 |
03:05 ET | 4501 | 17.43 |
03:07 ET | 6807 | 17.45 |
03:09 ET | 2682 | 17.4416 |
03:12 ET | 4324 | 17.43 |
03:14 ET | 1769 | 17.445 |
03:16 ET | 8367 | 17.43 |
03:18 ET | 4059 | 17.42 |
03:20 ET | 1818 | 17.42 |
03:21 ET | 2505 | 17.415 |
03:23 ET | 1500 | 17.425 |
03:25 ET | 5171 | 17.44 |
03:27 ET | 3940 | 17.445 |
03:30 ET | 3716 | 17.455 |
03:32 ET | 9375 | 17.435 |
03:34 ET | 3095 | 17.44 |
03:36 ET | 3495 | 17.445 |
03:38 ET | 3019 | 17.44 |
03:39 ET | 10378 | 17.41 |
03:41 ET | 3600 | 17.4 |
03:43 ET | 6608 | 17.4 |
03:45 ET | 6350 | 17.391 |
03:48 ET | 7724 | 17.395 |
03:50 ET | 14177 | 17.375 |
03:52 ET | 33389 | 17.37 |
03:54 ET | 9925 | 17.385 |
03:56 ET | 33486 | 17.4 |
03:57 ET | 21845 | 17.415 |
03:59 ET | 354415 | 17.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.7B | 79.0x | --- |
Twist Bioscience Corp | 2.7B | -13.9x | --- |
Maravai LifeSciences Holdings Inc | 2.8B | -11.2x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -5.9x | --- |
Vericel Corp | 2.3B | 4,980.1x | --- |
MorphoSys AG | 2.8B | -5.7x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.32 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 79.0x |
Price/Sales (TTM) | 9.3 |
Price/Cash Flow (TTM) | 65.1x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.